Sarizotan
- Generic Name
- Sarizotan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21FN2O
- CAS Number
- 351862-32-3
- Unique Ingredient Identifier
- 467LU0UCUW
- Indication
Investigated for use/treatment in schizophrenia and schizoaffective disorders and parkinson's disease.
- Associated Conditions
- -
- Associated Therapies
- -
Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 60
- Registration Number
- NCT00310661
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
🇮🇳Schizophrenia Research Foundation of India, Chennai, India
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
- First Posted Date
- 2005-03-16
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 506
- Registration Number
- NCT00105508
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
- First Posted Date
- 2005-03-16
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 398
- Registration Number
- NCT00105521
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath